



ten23 health announces major expansion in Switzerland with two new sterile manufacturing lines

The dedicated 5,000 square meter facility will provide an additional 30+ million units/year of fill and finish capacity. Raw construction is scheduled for completion in summer 2022 – the plant will be operational in 2024 and create more than 100 jobs.

- ten23 health will expand into an additional fully-dedicated building in Visp-West with around 5000 square meters of space. The raw construction superstructure is due to be completed in summer 2022
- The expansion will comprise two additional sterile manufacturing lines using Isolator technology
- One additional filling line will provide significant additional capacity for ready-to-use containers such as syringes and cartridges with 20 million unit annual capacity, as a true scale-up from its existing filling line in Visp.
- A third new manufacturing line with its two Lyophilizers will provide new capabilities for filling bulk containers (vials) in liquid and freeze-dried (lyophilized) dosage forms
- The expansions reflect the commitment of ten23 health to our activities in Visp, Valais, Switzerland and the increasing market demand in providing customized expert solutions for our customers and their patients globally

Basel, June 13, 2022. ten23 health®, a global contract development and manufacturing organization (CDMO) announced today an additional expansion of swissfillon's manufacturing site in Visp, canton of Valais, Switzerland, which was acquired October 2021. The FDA- and Swissmedic-inspected site in Visp currently offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and market supplies.

Today we announce the setup of a new manufacturing building in Visp-West, fully dedicated to ten23 health, which will provide around 5000 square meters of space over 4 floors. It has the capacity to accommodate a total of three additional manufacturing lines, technical areas and offices and laboratories. The superstructure of the building will be completed in summer 2022.

In this new facility in Visp-West, ten23 health plans to build two further sterile manufacturing lines: Sterile manufacturing line 2 will be a true scaled-up version of our existing filling line 1 and provide GMP fill & finish capacity for commercial as well as clinical use. The fill line will be based on latest Isolator technology and will be able to handle ready-to-use (RTU) containers including syringes, cartridges and special primary packaging such as used in specific administration devices for subcutaneous delivery. The annual total capacity of this line is estimated at 20 million units and the line is planned to be operational in 2024. Fill line 3 will broaden ten23 health's offering and capabilities with the ability to fill bulk containers (vials), both in liquid and lyophilized form, with two larger-scale freeze-driers, each at 12.5 square meters of shelf-space, for both clinical and commercial use. The annual total capacity of this line is estimated at 12.5 million units.

The two additional manufacturing lines will have great synergy with the existing production line in Visp, the development and testing services for sterile products in Basel, Switzerland as well as the expansion we announced on March-28, 2022 related to the addition of 1000 square meters of clean-room space for visual inspection and cold storage and supplementary services, such as device assembly.

The new building and production lines in Visp have the capacity to create more than 100 additional jobs in the region.

Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health, commented: *"The significant expansion of our production capacity for syringe and capsule filling, and technical capabilities of filling and lyophilization of sterile products in bulk vials is a clear commitment for Switzerland, and will enable our customers to provide treatment options for their patients."*

About ten23 health

ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Swissfillon, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly-owned subsidiary of ten23 health. ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called the Avogadro constant and equals 6.022×10^{23} . The world is built from small units, and not a homogeneous mass.

Media contacts:

ten23 health: Mara Willa, mara.willa@ten23.health; +41 27 948 31 70

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com; +44 20 7975 3021